RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) announced the granting of two patents in Europe related to its multi-needle dermal injection technologies.
The first patent has been validated in a total of 14 national countries and the second will also be validated in a number of European countries in the near future.
The first device being developed under these patents, RCI-02, is designed for injecting hyaluronic acid and other products as dermal fillers. The device is also being developed for the injection of RepliCel’s RCH-01 hair restoration and RCS-01 skin rejuvenation products. Future iterations of the technology and device will be optimized for other injectables, such as drugs, biologics, vaccines and fat grafts, for example.
“These patents are an important milestone for the Company as it underpins the near-term commercial value of RCI-02 for the delivery of other injectables beyond our own products,” CEO, Lee Buckler, said in a statement.
“RCI-02 coupled for the injection of dermal fillers and other aesthetic treatments represents an early opportunity for licensing and revenue,” he added.
This year, he said the company will build and test commercial-grade functioning prototypes with the goal of having it ready for a CE-mark application and potential market launch in 2018.
“Ongoing discussions with several multinational companies about potential commercial partnerships for the device give us confidence this represents one of RepliCel’s next licensing deals,” Mr. Buckler said.
